The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
um and one of those switches um basically jumped out of this analysis as like the top you know differentiator if you will um that expressed in Cancers and not um and others now it's a it's you know it's the type of molecule that historically has been thought to be challenging to create a drug against um there actually is a Proto drug against it that's you know still preclinical but you know moving forward we've been collaborating academically with that company
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.